Metabolism in Patients with Small Cell Lung Carcinoma Compared with Patients with Non-small Cell Lung Carcinoma and Healthy Controls

Overview

Journal Thorax

Date 1997 Apr 1

PMID 9196516

Citations 9

Authors

A M Schols

M A Dentener

G P ten Velde

W A Buurman

E F Wouters

Affiliations

Soon will be listed here.

Abstract

Background: Weight loss is a frequently occurring problem in patients with lung cancer due to an increased resting energy expenditure (REE) and a decreased energy intake. The aim of the present study was to compare the metabolic and inflammatory characteristics of patients with small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). The metabolic parameters of the lung cancer population were compared with those of a healthy control group.

Methods: REE was measured in 66 patients with lung cancer, subdivided according to their histology, and in 33 healthy controls matched for sex, age, and fat free mass (FFM). Inflammatory mediators were measured in the plasma of the patients with lung cancer.

Results: An increased REE adjusted for FFM was found in the patients with lung cancer. Those with small cell lung carcinoma (SCLC) had an increased REE adjusted for FFM (mean 1925 kcal/day) compared with those with non-small cell lung carcinoma (NSCLC) (mean 1789 kcal/day, 95% CI for difference 36 to 236). FFM accounted for 69% and 48% of the inter-individual variation in REE in controls and those with NSCLC, respectively, while FFM accounted for only 25% of the variation in REE in patients with SCLC in whom the fat mass (FM) also contributed significantly (28%) to the variation in REE. Increased concentrations of soluble TNF-receptor 75 (sTNF-R75) and cortisol were found in patients with SCLC compared with those with NSCLC. Lipopolyasccharide binding protein (LBP) and sTNF-R55 were related to plasma levels of cortisol.

Conclusion: An enhanced REE adjusted for FFM occurred in patients with SCLC compared with those with NSCLC.

Citing Articles

Small-cell lung cancer.

Rudin C, Brambilla E, Faivre-Finn C, Sage J Nat Rev Dis Primers. 2021; 7(1):3.

PMID: 33446664 PMC: 8177722. DOI: 10.1038/s41572-020-00235-0.

Sarcopenia and health-related quality of life in older adults after transcatheter aortic valve replacement.

Damluji A, Rodriguez G, Noel T, Davis L, Dahya V, Tehrani B Am Heart J. 2020; 224:171-181.

PMID: 32416332 PMC: 8132132. DOI: 10.1016/j.ahj.2020.03.021.

Histological subtype of lung cancer affects acceptance of illness, severity of pain, and quality of life.

Polanski J, Chabowski M, Jankowska-Polanska B, Janczak D, Rosinczuk J J Pain Res. 2018; 11:727-733.

PMID: 29692625 PMC: 5903479. DOI: 10.2147/JPR.S155121.

Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective.

Sanders K, E M Kneppers A, van de Bool C, Langen R, Schols A J Cachexia Sarcopenia Muscle. 2016; 7(1):5-22.

PMID: 27066314 PMC: 4799856. DOI: 10.1002/jcsm.12062.

The assessment and impact of sarcopenia in lung cancer: a systematic literature review.

Collins J, Noble S, Chester J, Coles B, Byrne A BMJ Open. 2014; 4(1):e003697.

PMID: 24384894 PMC: 3902311. DOI: 10.1136/bmjopen-2013-003697.

References

Patel A, DUNN W, Trastek V . Staging systems of lung cancer. Mayo Clin Proc. 1993; 68(5):475-82. DOI: 10.1016/s0025-6196(12)60197-9. View

Larsen K . Creatinine assay by a reaction-kinetic principle. Clin Chim Acta. 1972; 41:209-17. DOI: 10.1016/0009-8981(72)90513-x. View

Fong Y, Moldawer L, Marano M, Wei H, Barber A, Manogue K . Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol. 1989; 256(3 Pt 2):R659-65. DOI: 10.1152/ajpregu.1989.256.3.R659. View

FALCONER J, Fearon K, Plester C, Ross J, Carter D . Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994; 219(4):325-31. PMC: 1243147. DOI: 10.1097/00000658-199404000-00001. View

Hansell D, Davies J, Burns H . The effects on resting energy expenditure of different tumor types. Cancer. 1986; 58(8):1739-44. DOI: 10.1002/1097-0142(19861015)58:8<1739::aid-cncr2820580826>3.0.co;2-x. View

Russell D, Shike M, Marliss E, Detsky A, Shepherd F, Feld R . Effects of total parenteral nutrition and chemotherapy on the metabolic derangements in small cell lung cancer. Cancer Res. 1984; 44(4):1706-11. View

Tracey K, Wei H, Manogue K, Fong Y, Hesse D, Nguyen H . Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988; 167(3):1211-27. PMC: 2188883. DOI: 10.1084/jem.167.3.1211. View

Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D . A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989; 264(20):11974-80. View

Schols A, ten Velde G, Buurman W, Wouters E . Analysis of the energy balance in lung cancer patients. Cancer Res. 1994; 54(24):6430-3. View

10.

Westerterp K, Donkers J, Fredrix E, Boekhoudt P . Energy intake, physical activity and body weight: a simulation model. Br J Nutr. 1995; 73(3):337-47. DOI: 10.1079/bjn19950037. View

11.

Jebb S, Osborne R, Dixon A, Bleehen N, Elia M . Measurements of resting energy expenditure and body composition before and after treatment of small cell lung cancer. Ann Oncol. 1994; 5(10):915-9. DOI: 10.1093/oxfordjournals.annonc.a058730. View

12.

Fredrix E, Wouters E, Soeters P, Van der Aalst A, Kester A, Von Meyenfeldt M . Resting energy expenditure in patients with non-small cell lung cancer. Cancer. 1991; 68(7):1616-21. DOI: 10.1002/1097-0142(19911001)68:7<1616::aid-cncr2820680725>3.0.co;2-3. View

13.

Engelberts I, Stephens S, Francot G, van der Linden C, Buurman W . Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet. 1991; 338(8765):515-6. DOI: 10.1016/0140-6736(91)90591-c. View

14.

Dentener M, Schols A, Buurman W, Wouters E . Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol. 1995; 13(10):2600-5. DOI: 10.1200/JCO.1995.13.10.2600. View

15.

STRASSMANN G, Fong M, KENNEY J, Jacob C . Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992; 89(5):1681-4. PMC: 443047. DOI: 10.1172/JCI115767. View

16.

Fredrix E, Soeters P, Von Meyenfeldt M, Saris W . Measurement of resting energy expenditure in a clinical setting. Clin Nutr. 1990; 9(6):299-304. DOI: 10.1016/0261-5614(90)90001-9. View

17.

Ravussin E, Bogardus C . Relationship of genetics, age, and physical fitness to daily energy expenditure and fuel utilization. Am J Clin Nutr. 1989; 49(5 Suppl):968-75. DOI: 10.1093/ajcn/49.5.968. View

18.

Brockhaus M, BAR-KHAYIM Y, Gurwicz S, FRENSDORFF A, HARAN N . Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int. 1992; 42(3):663-7. DOI: 10.1038/ki.1992.332. View

19.

Kern K, Norton J . Cancer cachexia. JPEN J Parenter Enteral Nutr. 1988; 12(3):286-98. DOI: 10.1177/0148607188012003286. View

20.

Schaur R, Semmelrock H, SCHAUENSTEIN E, Kronberger L . Tumor host relations. II. Influence of tumor extent and tumor site on plasma cortisol of patients with malignant diseases. J Cancer Res Clin Oncol. 1979; 93(3):287-92. DOI: 10.1007/BF00964585. View